SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
GAITHERSBURG, Md., July 20, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will release its second quarter financial results immediately after market close on Thursday, August 3, 2017. The company will then conduct a conference call at 5:00 pm (Eastern Time) on the same day to discuss the financial results for the second quarter and year to date periods of 2017, recent business developments, revenue guidance for the third quarter of 2017, and revenue and net income guidance for full year 2017.
This conference call can be accessed live by telephone or via webcast:
Live Teleconference Information:
Dial in number: (855) 766-6521
Conference ID: 29703370
Live Webcast Information:
Visit edge.media-server.com/m/p/g8vcpsxx for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 [email protected]
